Daicel (4202) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
17 Jun, 2026Executive summary
Net sales for 1H FY2026/3 were ¥277.1bn, down 4.3% year-over-year, with operating income at ¥20.1bn, down 36.3%, reflecting a slowing global recovery and regional uncertainties, especially in China.
Profit attributable to owners of parent fell 41.3% year-over-year to ¥18.8bn.
Comprehensive income rose 15.8% year-over-year to ¥27,898 million, driven by gains in other comprehensive income.
Results were significantly impacted by foreign exchange fluctuations, lower sales in key segments, and regional uncertainties.
Revised full-year forecasts anticipate further declines in net sales and operating income compared to previous forecasts.
Financial highlights
EBITDA for 1H FY2026/3 was ¥40.5bn, down 21.2% year-over-year.
Gross profit for the period was ¥72,060 million, down from ¥84,003 million in the prior year.
EPS for the six months was ¥70.90, compared to ¥116.18 in the same period last year.
Total assets increased to ¥848,907 million as of September 30, 2025, up from ¥813,831 million at March 31, 2025.
Operating cash flow decreased to ¥32.8bn, with free cash flow at ¥6.2bn.
Outlook and guidance
Full-year net sales forecast revised to ¥583.0bn (down 2.8% from previous forecast), operating income to ¥46.5bn (down 13.9%).
Profit attributable to owners of parent forecast at ¥50.0bn, down 7.4% from previous forecast.
EPS for the full year is forecast at ¥188.33.
Annual dividend forecast maintained at ¥60 per share; treasury stock buyback of up to ¥15bn planned.
Latest events from Daicel
- Operating income fell 25% year-over-year, but healthcare and mobility segments grew.4202
Q1 202617 Jun 2026 - Strong 1H growth driven by plastics and Smart segment, but full-year net income guidance cut.4202
Q2 202517 Jun 2026 - Operating profit nearly doubled on strong demand and favorable exchange rates.4202
Q1 202517 Jun 2026 - Sales rose 5.1%, but profits declined; FY2026 outlook: higher sales, lower profits, stable dividends.4202
Q4 202517 Jun 2026 - Net sales up 4.4% year-over-year, but profit margins declined amid mixed segment results.4202
Q3 202517 Jun 2026 - Profits fell on lower sales, but healthcare and safety segments showed strong growth.4202
Q3 202617 Jun 2026 - Profits fell on impairment losses, but FY2027 net income is forecast to rebound strongly.4202
Q4 202617 Jun 2026